Maiko Hamada

USPTO Granted Patents = 12 (Patent Applications = 1)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 44(Granted Patents)

Location History:

Tokyo, JP (2011 - 2012)
Yamato, JP (2016)
Osaka, JP (2011 - 2024)

Company Filing History:

12 out of 257

Mitsubishi Tanabe Pharma Corporation

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12102641 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-10-01),

2. 11890288 - Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof (2024-02-06),

3. 11802135 - Lysophosphatidic acid derivative (2023-10-31),

4. 11542273 - Amide compound having bet proteolysis-inducing action and medicinal application thereof (2023-01-03),

5. 10407408 - Imide derivatives and use thereof as medicine (2019-09-10),

6. 9657043 - Amine compound and use thereof for medical purposes (2017-05-23),

7. 9527859 - Amidopyridine derivative and use thereof (2016-12-27),

8. 9150555 - Amide derivative and use thereof (2015-10-06),

9. 8129361 - Amine compound and pharmaceutical use thereof (2012-03-06),

10. 8114902 - 2-aminobutanol compound and use thereof for medical purposes (2012-02-14),

11. 8044042 - Thienotriazolodiazepine compound and medicinal use thereof (2011-10-25),

12. 7935700 - Morpholine compound (2011-05-03),

Title: Maiko Hamada: Pioneering Innovations in Cancer Therapeutics

Introduction

Maiko Hamada is a prominent inventor based in Osaka, Japan, celebrated for her groundbreaking contributions to the field of pharmaceutical science. With an impressive portfolio comprising 12 patents, her research focuses on developing compounds with therapeutic applications, particularly in the treatment of cancer.

Latest Patents

One of Maiko Hamada's latest patents is a sulfonamide or sulfinamide compound that facilitates the degradation of the BRD4 protein, a critical factor in cancer progression. This innovative compound or its pharmaceutically acceptable salts have shown promising efficacy as a therapeutic agent, providing hope in the fight against cancer. The detailed structure of the compound is defined within the patent description, showcasing its potential impact on medical treatments.

Career Highlights

Throughout her career, Maiko has made significant strides in pharmaceutical research while being associated with notable organizations such as Mitsubishi Tanabe Pharma Corporation and Osaka University. Her work not only exemplifies her commitment to innovation but also reflects her dedication to advancing therapeutic strategies that can save lives.

Collaborations

Collaboration has been a key element of Maiko Hamada's success. She has worked closely with esteemed colleagues such as Naoto Fujie and Minoru Tanaka, further enriching her research endeavors. These partnerships have played a vital role in refining her inventions and accelerating the development of her impactful patents.

Conclusion

Maiko Hamada stands as a beacon of innovation in the realm of pharmaceuticals, specifically in cancer therapeutics. Her dedication to research and collaboration has led to significant advancements, with her latest patents paving the way for potential breakthroughs in cancer treatment. As she continues her journey, her contributions are sure to inspire future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.